Orthofix Medical Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Sales Rise 2%, EPS at $(0.36) with $14.1M Net Loss
Orthofix Medical Inc. reported its financial results for the second quarter of 2025, showing net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs. Excluding the M6® discs, pro forma net sales reached $200.7 million, marking an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to the second quarter of 2024. The U.S. Spine Fixation segment experienced net sales growth of 5% and procedure volume growth of 7% compared to the same period last year. The company reported a net loss of $14.1 million, or $0.36 per share, on a reported basis. However, non-GAAP pro forma adjusted EBITDA was $20.6 million for the second quarter of 2025, representing a $4.0 million increase compared to the $16.6 million reported for the second quarter of 2024, reflecting a 24.1% growth over the prior year. Orthofix reaffirmed its full-year 2025 financial guidance and highlighted strategic initiatives, such as accelerating distributor transitions in underpenetrated U.S. territories, which are contributing to the company's ongoing transformation efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250805632737) on August 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.